Torrent R & D Centre has a team of over 560 scientists, who continue to offer dedicated services in the areas of Discovery Research, Generic Drug Development and New Drug Delivery Systems/Value added generics. Thereby transforming discoveries into the highest quality therapeutic products.

Set up at an investment of over US $ 40 million, the R&D Centre conforms to international quality standards and houses the most advanced and up to date equipments. It has one of the most advanced infrastructures for both basic and applied research.

Currently, Torrent has seven discovery projects in pipeline – 3 in Diabetes & related complications, 1 in cerebro-vascular, 2 in obesity and 1 in cardio-vascular. Torrent has filed 219 patents for NCEs in all major markets worldwide; the patent offices of USA, Japan, Europe, Czech Republic, Australia, Hong Kong, Russia and India have granted / accepted 123 patents so far.

Opportunities for undertaking contract and collaborative research are being actively pursued. There would be a distinct focus on out-licensing of its NCEs for development and global marketing.

The Establishment ::

• Total land area: 125,000 sq mts
• Built-up area: 38,000 Sq mts
• Laboratories: 24,000 Sq mts
• Support services: 14,000 Sq mts
• Investment: US $ 40 million

Unique Architectural Feature ::
It was specially designed with passive downdraft evaporative cooling which saves the air-conditioning plant capacity by about 150 T.R.

Goals ::
To develop safe and effective therapeutic options for undiscovered and unmet medical needs.

• To be the most productive Research and Development Centre.
• Quality remains an essential attribute in all aspects and activities at the R&D Centre.

Objectives ::

• To develop capabilities to design and synthesize new chemical entities based on advances in patho-physiology and therapeutic modalities in selected treatment areas and provisions for out licensing them at the appropriate stage of development.
• To evaluate their therapeutic and safety profile and guide the lead entities through the process of development to a stage of clinical application.
• To provide "incremental innovation" for existing products i.e. to look for new indications, to develop innovative, therapeutically beneficial formulations to extend the product life and the market segment.
• To develop methods of analysis, lay down specifications and work out quality assurance norms in relation to all the above activities and in doing so, to facilitate the process of scaling up from laboratory scale to plant and towards regular production.
• To assess developments and advances worldwide with a view to licensing in or buying in technologies at an early date and to assimilate and improve upon them for commercial production.
• To build and maintain a good scientific reputation and provide intellectual stimulation for the Torrent staff through continuous interaction with academia and contribution to science and to inculcate a "Scientific Temper" amongst its technical members.
• To be conversant with advances in all spheres of healthcare and to evaluate the desirability of venturing into new areas.

National / International Alliances :

The Torrent R&D Centre is focused on developing safe and effective therapeutic options for undiscovered and unmet medical needs. Complementing Torrent’s advanced R&D infrastructure and facilities, are its alliances with several leading institutions/pharma majors.

     • Astra Zeneca, Sweden, U.K
     • Birla Institute of Technology, Pilani
     • M. S. University, Baroda
     • University of Pune, Pune